Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.
2.

Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review.

Milling TJ, Fromm C, Ganetsky M, Pallin DJ, Cong J, Singer AJ.

Ann Emerg Med. 2017 May;69(5):531-540. doi: 10.1016/j.annemergmed.2016.11.040. Epub 2017 Feb 10.

3.

Preclinical and clinical data for factor Xa and "universal" reversal agents.

Milling TJ Jr, Kaatz S.

Am J Emerg Med. 2016 Nov;34(11S):39-45. doi: 10.1016/j.ajem.2016.09.052. Epub 2016 Sep 28. Review.

4.

Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed.

Milling TJ Jr, Spyropoulos AC.

Am J Emerg Med. 2016 Nov;34(11S):19-25. doi: 10.1016/j.ajem.2016.09.049. Epub 2016 Sep 28. Review.

5.

Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.

Milling TJ Jr, Kaatz S.

Am J Med. 2016 Nov;129(11S):S80-S88. doi: 10.1016/j.amjmed.2016.06.009. Epub 2016 Aug 27. Review.

6.

Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators.

N Engl J Med. 2016 Sep 22;375(12):1131-41. doi: 10.1056/NEJMoa1607887. Epub 2016 Aug 30.

7.

Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed.

Milling TJ Jr, Spyropoulos AC.

Am J Med. 2016 Nov;129(11S):S54-S63. doi: 10.1016/j.amjmed.2016.06.006. Epub 2016 Aug 26. Review.

8.

Prospective validation of a biomarker panel to identify pediatric ED patients with abdominal pain who are at low risk for acute appendicitis.

Huckins DS, Simon HK, Copeland K, Milling TJ Jr, Spandorfer PR, Hennes H, Allen C, Gogain J; APAB Study Group.

Am J Emerg Med. 2016 Aug;34(8):1373-82. doi: 10.1016/j.ajem.2016.03.066. Epub 2016 Apr 5.

PMID:
27133536
9.

Safety of a Four-factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials.

Milling TJ Jr, Refaai MA, Sarode R, Lewis B, Mangione A, Durn BL, Harman A, Lee ML, Goldstein JN.

Acad Emerg Med. 2016 Apr;23(4):466-75. doi: 10.1111/acem.12911. Epub 2016 Mar 21.

10.

Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal.

Refaai MA, Goldstein JN, Lee ML, Durn BL, Milling TJ Jr, Sarode R.

Transfusion. 2015 Nov;55(11):2722-9. doi: 10.1111/trf.13191. Epub 2015 Jul 1.

11.

Thromboembolic Events After Vitamin K Antagonist Reversal With 4-Factor Prothrombin Complex Concentrate: Exploratory Analyses of Two Randomized, Plasma-Controlled Studies.

Milling TJ Jr, Refaai MA, Goldstein JN, Schneider A, Omert L, Harman A, Lee ML, Sarode R.

Ann Emerg Med. 2016 Jan;67(1):96-105.e5. doi: 10.1016/j.annemergmed.2015.04.036. Epub 2015 Jun 17.

12.

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Lancet. 2015 May 23;385(9982):2077-87. doi: 10.1016/S0140-6736(14)61685-8. Epub 2015 Feb 27.

PMID:
25728933
13.

Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population.

Welch RD, Nicholas K, Durkalski-Mauldin VL, Lowenstein DH, Conwit R, Mahajan PV, Lewandowski C, Silbergleit R; Neurological Emergencies Treatment Trials (NETT) Network Investigators.

Epilepsia. 2015 Feb;56(2):254-62. doi: 10.1111/epi.12905. Epub 2015 Jan 17.

14.

Very early administration of progesterone for acute traumatic brain injury.

Wright DW, Yeatts SD, Silbergleit R, Palesch YY, Hertzberg VS, Frankel M, Goldstein FC, Caveney AF, Howlett-Smith H, Bengelink EM, Manley GT, Merck LH, Janis LS, Barsan WG; NETT Investigators.

N Engl J Med. 2014 Dec 25;371(26):2457-66. doi: 10.1056/NEJMoa1404304. Epub 2014 Dec 10.

15.

Degradation of benzodiazepines after 120 days of EMS deployment.

McMullan JT, Jones E, Barnhart B, Denninghoff K, Spaite D, Zaleski E, Silbergleit R; Neurological Emergencies Treatment Trials investigators.

Prehosp Emerg Care. 2014 Jul-Sep;18(3):368-74. doi: 10.3109/10903127.2013.869642. Epub 2014 Feb 18.

16.

Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.

Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, Goldstein JN.

Circulation. 2013 Sep 10;128(11):1234-43. doi: 10.1161/CIRCULATIONAHA.113.002283. Epub 2013 Aug 9.

17.

The 60-day temperature-dependent degradation of midazolam and Lorazepam in the prehospital environment.

McMullan JT, Pinnawin A, Jones E, Denninghoff K, Siewart N, Spaite DW, Zaleski E, Silbergleit R; Neurological Emergencies Treatment Trials investigators.

Prehosp Emerg Care. 2013 Jan-Mar;17(1):1-7. doi: 10.3109/10903127.2012.722177. Epub 2012 Nov 13.

18.

Heparin-induced thrombocytopenia associated with massive intracardiac thrombosis: a case report.

Ahmed A, Al-Mondhiry H, Milling TJ Jr, Campbell D.

Case Rep Hematol. 2012;2012:257023. doi: 10.1155/2012/257023. Epub 2012 Mar 29.

19.

The GENESIS project (GENeralized Early Sepsis Intervention Strategies): a multicenter quality improvement collaborative.

Cannon CM, Holthaus CV, Zubrow MT, Posa P, Gunaga S, Kella V, Elkin R, Davis S, Turman B, Weingarten J, Milling TJ Jr, Lidsky N, Coba V, Suarez A, Yang JJ, Rivers EP.

J Intensive Care Med. 2013 Nov-Dec;28(6):355-68. doi: 10.1177/0885066612453025. Epub 2012 Aug 17.

PMID:
22902347
20.

Implementation of the exception from informed consent regulations in a large multicenter emergency clinical trials network: the RAMPART experience.

Silbergleit R, Biros MH, Harney D, Dickert N, Baren J; NETT Investigators.

Acad Emerg Med. 2012 Apr;19(4):448-54. doi: 10.1111/j.1553-2712.2012.01328.x.

Supplemental Content

Loading ...
Support Center